BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 16490239)

  • 1. Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning.
    Hensley ML; Correa DD; Thaler H; Wilton A; Venkatraman E; Sabbatini P; Chi DS; Dupont J; Spriggs D; Aghajanian C
    Gynecol Oncol; 2006 Aug; 102(2):270-7. PubMed ID: 16490239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer.
    Micha JP; Goldstein BH; Rettenmaier MA; Mattison J; Graham C; Birk CL; Brown JV
    Gynecol Oncol; 2004 Sep; 94(3):719-24. PubMed ID: 15350364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer.
    Micha JP; Goldstein BH; Mattison JA; Bader K; Graham C; Rettenmaier MA; Brown JV; Markman M
    Gynecol Oncol; 2005 Jan; 96(1):132-5. PubMed ID: 15589591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.
    Gordon AN; Teneriello M; Janicek MF; Hines J; Lim PC; Chen MD; Vaccarello L; Homesley HD; McMeekin S; Burkholder TL; Wang Y; Zhao L; Orlando M; Obasaju CK; Gill JF; Tai DF
    Gynecol Oncol; 2011 Dec; 123(3):479-85. PubMed ID: 21978765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan.
    Liu FS; Ho ES; Hung MJ; Hwang SF; Lu CH; Ke YM
    Gynecol Oncol; 2004 Aug; 94(2):393-7. PubMed ID: 15297178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
    Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
    Trials; 2015 Dec; 16():575. PubMed ID: 26673577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Look KY; Bookman MA; Schol J; Herzog TJ; Rocereto T; Vinters J;
    Gynecol Oncol; 2004 Jan; 92(1):93-100. PubMed ID: 14751144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first-line treatment of advanced ovarian cancer: A phase II study.
    Mäenpää JU; Grénman SE; Jalkanen JT; Kuoppala TA; Leminen AO; Puistola US; Vuolo-Merilä PM; Yliskoski MH
    Gynecol Oncol; 2006 Apr; 101(1):114-9. PubMed ID: 16266743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel.
    Edelman MJ; Gandara DR; Lau DH; Lara P; Lauder IJ; Tracy D
    Cancer; 2001 Jul; 92(1):146-52. PubMed ID: 11443620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer.
    Harries M; Moss C; Perren T; Gore M; Hall G; Everard M; A'Hern R; Gibbens I; Jenkins A; Shah R; Cole C; Pizzada O; Kaye S
    Br J Cancer; 2004 Aug; 91(4):627-32. PubMed ID: 15238984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
    Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
    Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
    Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).
    Schallier D; Neyns B; Fontaine C; Steene JV; De Mey J; Meysman M; De Grève J
    Lung Cancer; 2007 May; 56(2):247-54. PubMed ID: 17337086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study.
    Steer CB; Chrystal K; Cheong KA; Galani E; Marx GM; Strickland AH; Yip D; Lofts F; Gallagher C; Thomas H; Harper PG
    Gynecol Oncol; 2006 Nov; 103(2):439-45. PubMed ID: 16643993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer.
    du Bois A; Herrstedt J; Hardy-Bessard AC; Müller HH; Harter P; Kristensen G; Joly F; Huober J; Avall-Lundqvist E; Weber B; Kurzeder C; Jelic S; Pujade-Lauraine E; Burges A; Pfisterer J; Gropp M; Staehle A; Wimberger P; Jackisch C; Sehouli J
    J Clin Oncol; 2010 Sep; 28(27):4162-9. PubMed ID: 20733132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of sequential chemotherapy with carboplatin plus gemcitabine followed by weekly paclitaxel in advanced non-small cell lung cancer.
    Soetekouw PM; Timmer-Bonte JN; van der Drift MA; van Leeuwen F; Wagenaar M; van Die L; Bussink J; Tjan-Heijnen VC
    Int J Clin Oncol; 2013 Dec; 18(6):988-96. PubMed ID: 23011101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8).
    du Bois A; Belau A; Wagner U; Pfisterer J; Schmalfeldt B; Richter B; Staehle A; Jackisch C; Lueck HJ; Schroeder W; Burges A; Olbricht S; Elser G;
    Gynecol Oncol; 2005 Feb; 96(2):444-51. PubMed ID: 15661234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
    Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W
    Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel - pretreated ovarian carcinoma.
    Pectasides D; Pectasides E; Papaxoinis G; Psyrri A; Pliarchopoulou K; Koumarianou A; Macheras A; Athanasas G; Xiros N; Economopoulos T
    Gynecol Oncol; 2010 Jul; 118(1):52-7. PubMed ID: 20406710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer.
    Friedlander M; Buck M; Wyld D; Findlay M; Fitzharris B; De Souza P; Davies T; Kalimi G; Allan S; Perez D; Harnett P
    Int J Gynecol Cancer; 2007; 17(2):350-8. PubMed ID: 17362312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.